Development of A HTLV-1 Vaccine

Project: Research project

Project Details


PROJECT NARRATIVE Human T cell leukemia virus type-1 (HTLV-1) is a human retrovirus that is the causative agent of a malignant T CD4+ cell lymphoproliferation referred to as Adult T cell leukemia/lymphoma (ATLL), as well as several inflammatory disorders with the most problematic being human myelopathy/tropical spastic paraparesis (HAM/TSP). Remarkable, while millions are affected worldwide, there is no effective vaccine or treatment options to prevent ATL or HAM/TSP afflicted individuals. We thus aim here, to develop a candidate vaccine to prevent and plausibly treat HTLV1-associated disease.
Effective start/end date3/3/212/28/23


  • National Cancer Institute: $623,689.00
  • National Cancer Institute: $540,678.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.